Microbial modulation of the gut microbiome for treating autoimmune diseases

Expert Review of Gastroenterology and Hepatology

Volumn 12, Issue 10, 2018, Pages 985-996

  Balakrishnan, Baskar ^a   Taneja, Veena ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

autoimmune diseases; Gut microbes; gut modulation; next generation probiotics; therapeutic probiotics

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

AKKERMANSIA MUCINIPHILA; ANTIMICROBIAL THERAPY; AUTOIMMUNE DISEASE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; CLINICAL STUDY; DIETARY INTAKE; FAECALIBACTERIUM PRAUSNITZII; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; NONHUMAN; PRECLINICAL STUDY; PREVOTELLA; PREVOTELLA HISTICOLA; REVIEW; SPECIES COMPOSITION; DIET; IMMUNOLOGY; MICROBIOLOGY; TRANSGENIC MICROORGANISM; VERRUCOMICROBIA;

ANTI-BACTERIAL AGENTS; AUTOIMMUNE DISEASES; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; DIET; FAECALIBACTERIUM PRAUSNITZII; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; MICROORGANISMS, GENETICALLY-MODIFIED; PREVOTELLA; PROBIOTICS; VERRUCOMICROBIA;

EID: 85054642382     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2018.1517044     Document Type: Review

References (129)

1. Mueller NT, Bakacs E, Combellick J, et al. The infant microbiome development: mom matters. Trends Mol Med. 2015;21:109–117.
2. Yang I, Corwin EJ, Brennan PA, et al. The infant microbiome: implications for infant health and neurocognitive development. Nurs Res. 2016;65:76–88.
3. Tanaka M, Nakayama J., Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017;66:515–522.
4. Ignacio A, Morales CI, Câmara NOS, et al. Innate sensing of the gut microbiota: modulation of inflammatory and autoimmune diseases. Front Immunol. 2016;77:54.
5. Oliveira GLV, Leite AZ, Higuchi BS, et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017;152:1–12.
6. Trowsdale J. The MHC, disease and selection. Immunol Lett. 2011;137:1–8.
7. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Me. 2015;278:369–395.
8. + -adenosine triphosphatase in human gastric autoimmunity. J Exp Med. 2003;198:1147–1156.
9. Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014;33:314–329.
10. Wang L, Wang FS, Chang C, et al. Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis. 2014;34:297–317.
11. Laurence M, Benito-León J. Epstein–Barr virus and multiple sclerosis: updating Pender’s hypothesis. Mult Scler Relat Disord. 2017;16:8–14.
12. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563.
13. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718–15723.
14. Chen J, Wright K, Davis JM, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8:43.
15. Fujisaka S, Avila-Pacheco J, Soto M, et al. Diet, genetics, and the gut microbiome drive dynamic changes in plasma metabolites. Cell Rep. 2018;22:3072–3086.
16. Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. Lupus. 2014;23:518–526.
17. Wisniewski JR, Friedrich A, Keller T, et al. The impact of high-fat diet on metabolism and immune defense in small intestine mucosa. J Proteome Res. 2015;14:353–365.
18. Gibson GR, Probert HM, Loo JV, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev. 2004;17:259–275.
19. Gibson G, Roberfroid M. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
20. McCarville JL, Caminero A, Verdu EF. Novel perspectives on therapeutic modulation of the gut microbiota. Therap Adv Gastroenterol. 2016;9:580–593.
21. Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016;8:46.
22. Makki K, Deehan EC, Walter J, et al. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23:705–715.
23. Shibata N, Kunisawa J, Kiyono H. Dietary and microbial metabolites in the regulation of host immunity. Front Microbiol. 2017;8:2171.
24. Bolognini D, Tobin AB, Milligan G, et al. The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol. 2016;89:388–398.
25. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–450.
26. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–573.
27. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40:128–139.
28. Kaiko GE, Ryu SH, Koues OI, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165:1708–1720.
29. Kunisawa J, Kiyono H. Vitamin-mediated regulation of intestinal immunity. Front Immunol. 2013;4:189.
30. Suzuki H, Kunisawa J. Vitamin-mediated immune regulation in the development of inflammatory diseases. Endocrine Metab Immune Disord Drug Targets. 2015;15:212–215.
31. 12 as a modulator of gut microbial ecology. Cell Metab. 2014;20:769–778.
32. Zhao Y, Wu J, J V L, et al. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013;12:2987–2999.
33. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr Int J Paediatr. 2009;98:229–238.
34. Wang Y, Wang B, Wu J, et al. Modulation of gut microbiota in pathological states. Engineering. 2017;3:83–89.
35. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546–551.
36. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108:4554–4561.
37. Weingarden A, González A, Vázquez-Baeza Y, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015;3:10.
38. Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015;21:102–111.
39. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142–149.
40. Qin J, Li R, Raes J, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010;464:59–65.
41. Song Y, Garg S, Girotra M, et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS ONE. 2013;8:e81330.
42. Eppinga H, Fuhler GM, Peppelenbosch MP, et al. Gut microbiota developments with emphasis on inflammatory bowel disease: report from the gut microbiota for health world summit 2016. Gastroenterology. 2016;151:e1–4.
43. Ridaura VK, Faith JJ, Rey FE, et al. Cultured gut microbiota from twins discordant for obesity modulate adiposity and metabolic phenotypes in mice. Science. 2013;341:1241214.
44. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811.
45. Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neuropsychiatric disorders. Clin Psychopharmacol Neurosci. 2016;14:231.
46. Bron PA, Kleerebezem M, Brummer RJ, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr. 2017;117:93–107.
47. Yadav H, Lee J-H, Lloyd J, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288:25088–25097.
48. Dolpady J, Sorini C, Di Pietro C, et al. Probiotc VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment. J Diabetes Res. 2016;2016:7569431.
49. So JS, Kwon HK, Lee CG, et al. Lactobacillus casei suppresses experimental arthritis by down regulating T helper 1 effector functions. Mol Immunol. 2008;45:2690–2699.
50. So JS, Lee CG, Kwon HK, et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol. 2008;46:172–180.
51. Maassen CBM, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine. 2008;26:2056–2057.
52. Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185:4101–4108.
53. Takata K, Kinoshita M, Okuno T, et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS ONE. 2011;6:e27644.
54. Kwon HK, Kim GC, Kim Y, et al. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin Immunol. 2013;146:217–227.
55. Kouchaki E, Tamtaii OR, Salami M, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36:1245–1249.
56. Pineda MA, Thompson SF, Summers K, et al. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit. 2011;17:CR347–54.
57. Abhari K, Shekarforoush SS, Hosseinzadeh S, et al. The effects of orally administered Bacillus coagulans and inulin on prevention and progression of rheumatoid arthritis in rats. Food Nutr Res. 2016;60:30876.
58. Spinler J, Taweechotipatr M, Rognerud C, et al. Human derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe. 2008;14:166–171.
59. O’Shea E, Cotter P, Stanton C, et al. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol. 2011;152:189–205.
60. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Ther Adv Gastroenterol. 2013;6:39–51.
61. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–672.
62. Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host & Microbe. 2015;17:662–671.
63. DeVuyst L, Moens F, Selak M. Summer meeting 2013: growth and physiology of Bifidobacteria. J App Microbiol. 2014;116:477–491.
64. Walker AW, Duncan SH, Louis P. Phylogeny, culturing, and metagenomics of the human gut microbiota. Trends Microbiol. 2014;22:267–274.
65. Cani PD, Van Hul M. Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr Opin Biotechnol. 2015;32:21–27.
66. Scott KP, Antoine JM, Midtvedt T. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis. 2015;26:25877.
67. Leahy SC, Higgins DG, Fitzgerald GF. Getting better with Bifidobacteria. J Appl Microbiol. 2005;98:1303–1315.
68. Di Gioia D, Aloisio I, Mazzola G. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants. Appl Microbiol Biotechnol. 2014;98:563–577.
69. Tojo R, Suárez A, Clemente MG. Intestinal microbiota in health and disease: role of bifidobacterial in gut homeostasis. World J Gastroenterol. 2014;20:15163–15176.
70. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J. The role of probiotic lactic acid bacteria and bifidobacterial in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015;2015:505878.
71. Rivière A, Gagnon M, Weckx S. Mutual cross-feeding interactions between Bifidobacterium longum NCC2705 and Eubacterium rectale ATCC33656 explain the bifidogenic and butyrogenic effects of arabinoxylan-oligosaccharides. Appl Environ Microbiol. 2015;81:7767–7781.
72. Eeckhaut V, Machiels K, Perrier C. Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut. 2013;62:1745–1752.
73. Eeckhaut V, Ducatelle R, Sas B. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics. Gut. 2014;63:367.
74. Martín R, Miquel S, Chain F. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 2015;15:67.
75. Braat H, Van Den Brande J, Van Tol E, et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr. 2004;80:1618–1625.
76. Schultz M, Linde HJ, Lehn N, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70:165–173.
77. Liu Y-J, Soumelis V, Watanabe N, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193–219.
78. Moore KW, De Waal Malefyt R, Coffman RL, et al. Interleukin 10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
79. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev. 2008;226:172–190.
80. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, et al. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact. 2009;8:17.
81. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015;14:137.
82. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–1355.
83. Caluwaerts S, Vandenbroucke K, Steidler L, et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010;46:564–570.
84. Robert S, Steidler L. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the type 1 diabetes case. Microb Cell Fact. 2014;13:S11.
85. Hamady ZZ, Scott N, Farrar MD, et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut. 2010;59:461–469.
86. Hamady ZZ, Scott N, Farrar MD, et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis. 2011;17:1925–1935.
87. Farrar MD, Whitehead TR, Lan J, et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan. J Appl Microbiol. 2005;98:1191–1197.
88. Whelan RA, Rausch S, Ebner F, et al. A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol Ther. 2014;22:1730–1740.
89. Maier E, Anderson RC, Roy NC. Understanding how commensal obligate anaerobic bacteria regulate immune functions in the large intestine. Nutrients. 2015;7:45–73.
90. Derrien M, Van Baarlen P, Hooiveld G, et al. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol. 2011;2:166.
91. Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2017; Doi:10.1136/gutjnl-2017-314508.
92. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
93. Kaiser J. Gut microbes shape response to cancer immunotherapy. Science. 2017;358:573.
94. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066–9071.
95. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107–113.
96. Hage ER, Hernandez-Sanabria E, Van de Wiele T. Emerging trends in “smart probiotics”: functional consideration for the development of novel health and industrial applications. Front Microbiol. 2017;8:1889.
97. Mahowald MA, Rey FE, Seedorf H, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc. Natl Acad Sci U S A. 2009;106:5859–5864.
98. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-γ and ReIA. Nat Immunol. 2004;5:104–112.
99. Wrzosek L, Miquel S, Noordine ML, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013;11:61.
100. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20:593–621.
101. Round JL, Lee SM, Li J, et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974–977.
102. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–1463.
103. Zhang W, Zhu B, Xu J, et al. Bacteroides fragilis protects against antibiotic associated diarrhea in rats by modulating intestinal defenses. Front Immunol. 2018;9:1040.
104. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620–625.
105. Rossi O, Van Berkel LA, Chain F, et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016;6:18507.
106. Chung WS, Walker AW, Louis P, et al. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol. 2016;1:3.
107. Martín R, Miquel S, Benevides L, et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol. 2017;8:1226.
108. Qiu X, Zhang M, Yang X, et al. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohn’s Colitis. 2013;11:e558–68.
109. Filippo CD, Cavalieri D, Paola MD, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–14696.
110. Pianta A, Arvikar S, Strle K, et al. Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69:964–975.
111. Marietta EV, Murray JA, Luckey DH, et al. Human gut-derived Prevotella histicola suppresses inflammatory arthritis in humanized mice. Arthritis Rheumatol. 2016;68:2878–2888.
112. Mangalam A, Shahi SK, Luckey D, et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 2017;20:1269–1277.
113. Taneja V. Arthritis susceptibility and the gut microbiome. FEBS Lett. 2014;588:4244–4249.
114. Gomez A, Yoeman C, Luckey D, White BA, Taneja V, et al. Loss of sex and age-driven differences in the gut microbiome characterize arthritis-susceptible *0401 mice but not arthritis-resistant *0402 mice. PLoS ONE. 2012;7:e36095.
115. Heidebach T, Först P, Kulozik U. Microencapsulation of probiotic cells for food applications. Crit Rev Food Sci Nutr. 2012;52:291–311.
116. Paulo Sousa E Silva J, Freitas AC. Probiotic bacteria. 1st ed. Singapore: Pan Stanford Publishing; 2014.
117. Brodmann T, Endo A, Gueimonde M, et al. Safety of novel microbes for human consumption: practical examples of assessment in the European Union. Front Microbiol. 2017;8:1725.
118. Arora M, Baldi A. Regulatory categories of probiotics across the globe: a review representing existing and recommended categorization. Indian J Med Microbiol. 2015;33:2–10.
119. Podolsky SH. Metchnikoff and the microbiome. Lancet. 2012;380:1810–1811.
120. Gomez A, Luckey D, Taneja V. The gut microbiome in autoimmunity: sex matters. Clin Immunol. 2015;159:154–162.
121. Vieira M, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359:1156–1161.
122. Vandenbroucke K, De Haard H, Beirnaert E, et al. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010;3:49–56.
123. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004;127:502–513.
124. Foligne B, Dessein R, Marceau M, et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology. 2007;133:862–874.
125. Watterlot L, Rochat T, Sokol H, et al. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol. 2010;144:35–41.
126. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754–759.
127. Hanson ML, Hixon JA, Li W, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014;146:210–221:e213.
128. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest. 2012;122:1717–1725.
129. Ma Y, Liu J, Hou J, et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLoS ONE. 2014;9:e105701vv.